Munari Sara, Ciotti Giulia, Cestaro Walter, Corsi Lorenzo, Tonin Silvia, Ballarin Andrea, Floriani Ariel, Dartora Cristina, Bosi Annamaria, Tacconi Matteo, Gialdini Francesco, Gottardi Michele, Menzella Francesco
Otolaryngology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.
Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.
Drugs Context. 2024 May 22;13. doi: 10.7573/dic.2024-3-5. eCollection 2024.
Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. These drugs are safe, but temporary iatrogenic hypereosinophilia may sometimes be associated with clinical symptoms or organ damage. Here, we describe a case of severe hypereosinophilia in a patient with chronic rhinosinusitis with nasal polyps and asthma treated with dupilumab and a subsequent therapeutic shift to mepolizumab that led to maintenance of symptom control and concomitant normalization of blood eosinophil count.
2型炎症是一种异质性疾病，原因是不同免疫途径的复杂激活。在评估生物制剂对伴有鼻息肉的慢性鼻-鼻窦炎和哮喘疗效的研究方面取得的快速进展，已带来了有效的治疗选择。这些药物是安全的，但有时短暂的医源性嗜酸性粒细胞增多可能与临床症状或器官损伤有关。在此，我们描述了1例伴有鼻息肉的慢性鼻-鼻窦炎和哮喘患者，在用度普利尤单抗治疗后出现严重嗜酸性粒细胞增多，随后治疗转向美泊利单抗，从而维持了症状控制并使血液嗜酸性粒细胞计数同时恢复正常的病例。
